Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH, Conference Calls/ Webcasts

Option Care Health to Announce Second Quarter 2023 Financial Results and Host Conference Call


BANNOCKBURN, Ill., July 06, 2023 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, today announced that the company will release results for its second quarter ended June 30, 2023 on Thursday, July 27, 2023 before the market opens. In conjunction, the management team will host a conference call to review the results at 8:30 a.m. E.T. on the same day.

Conference Call Details

Participants can pre-register for the conference call at the following link: https://register.vevent.com/register/BI9729f01ef2814b10889a52384611335e. The call can also be accessed via a live audio webcast that will be available online at https://investors.optioncarehealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

For Investor Inquiries:

Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
[email protected]



These press releases may also interest you

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor...

at 07:05
Alentis Therapeutics ("Alentis"), a clinical-stage biotechnology company developing treatments for organ fibrosis and Claudin-1 positive tumors, announced today that Dr. Alberto Toso has been appointed as Chief Scientific Officer effective...

at 07:05
Deciphera Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it has entered into a definitive merger...

at 07:05
bit.bio, the company coding human cells for novel cures, and a pioneer in the field of synthetic biology, today announces it will participate in an engaging fireside chat at SynBioBeta 2024 featuring Nobel Laureate Thomas Südhof and bit.bio founder...

at 07:05
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter...

at 07:05
Positive high-level results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to...



News published on and distributed by: